Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase

被引:14
|
作者
Bhojwani, Heena R. [1 ]
Joshi, Urmila J. [1 ]
机构
[1] Univ Mumbai, Prin KM Kundnani Coll Pharm, Dept Pharmaceut Chem, Mumbai, Maharashtra, India
关键词
DFG-motif; docking; virtual screening; pharmacophore; quantitative structure-activity relationship; type I inhibitor; VEGFR-2; TYROSINE KINASES; PROTEIN-KINASES; DRUG DISCOVERY; DESIGN; POTENT; IDENTIFICATION; ANGIOGENESIS; PERMEABILITY; CONFORMATION; TARGETS;
D O I
10.2174/1386207319666161214112536
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Kinase domain of VEGFR-2 displays conformational flexibility which leads to existence of two kinds of inhibitors viz. type I and type II inhibitors. They exhibit different binding modes and this necessitates the development of separate pharmacophore models for them. Methods: The virtual screening study for discovery of type I inhibitors of VEGFR-2 kinase was done by using combined pharmacophore (generated using PHASE and validated by 3D-QSAR) and docking (Glide) based approach. Validated pharmacophore was used as preliminary filter followed by docking. ADME properties were predicted for retrieved hits using QikProp. Results: ADHRR.94 with statistical parameters r(test)(2)0.94, r(training)(2)0.99, SD 0.0766, r(2)0.9861, F 283.3, RMSE 0.2605, q(2)0.8115 and Pearson's R 0.9723 was identified as the best pharmacophore hypothesis for type I inhibitors of VEGFR-2 kinase. Virtual screening study was done for Asinex Elite Libraries comprising of 104400 molecules using ADHRR. 94, HTVS docking and XP docking that resulted in twelve hits. Asinex ligand 5686 with docking score of -10.48kcal/mol was top-ranking hit. It made two hydrogen bonding interactions with Cys 919, one as an acceptor and other as a donor, which are characteristic of type I inhibitors. Additional interactions observed were pi-cation with Lys 868 and pi-pi stacking with Phe 1047. Twelve hits had acceptable values for ADME properties. Conclusion: Twelve hits with best obtained docking scores ranging from -10.48 to - 7.23 kcal/mol and mimicking characteristic type I inhibitor interactions were identified which could be probable inhibitors of VEGFR-2.
引用
收藏
页码:186 / 207
页数:22
相关论文
共 50 条
  • [31] Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors
    Gupta, A. K.
    Bhunia, S. S.
    Balaramnavar, V. M.
    Saxena, A. K.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2011, 22 (3-4) : 239 - 263
  • [32] Discovery of Rho-kinase inhibitors by docking-based virtual screening
    Shen, Mingyun
    Yu, Huidong
    Li, Youyong
    Li, Pixu
    Pan, Peichen
    Zhou, Shunye
    Zhang, Liling
    Li, Shang
    Lee, Simon Ming-Yuen
    Hou, Tingjun
    MOLECULAR BIOSYSTEMS, 2013, 9 (06) : 1511 - 1521
  • [33] Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking
    Miao-miao Niu
    Jing-yi Qin
    Cai-ping Tian
    Xia-fei Yan
    Feng-gong Dong
    Zheng-qi Cheng
    Guissi Fida
    Man Yang
    Haiyan Chen
    Yue-qing Gu
    Acta Pharmacologica Sinica, 2014, 35 : 967 - 979
  • [34] Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking
    Niu, Miao-miao
    Qin, Jing-yi
    Tian, Cai-ping
    Yan, Xia-fei
    Dong, Feng-gong
    Cheng, Zheng-qi
    Fida, Guissi
    Yang, Man
    Chen, Hai-yan
    Gu, Yue-qing
    ACTA PHARMACOLOGICA SINICA, 2014, 35 (07) : 967 - 979
  • [35] Novel VEGFR-2 kinase inhibitors for the treatment of cancer
    Boyer, SJ
    Burke, JM
    Brennan, CR
    Brini, W
    Collibee, W
    Dixon, JA
    Dumas, J
    Ehrgott, F
    Hatoum-Mokdad, H
    Hong, ZQ
    Kluender, HC
    Lee, W
    Ma, X
    Reeves, R
    Sibley, RN
    Turner, T
    Wong, W
    Zhang, YL
    Brink, C
    Carter, C
    Chang, Y
    Chien, DS
    Cortes, C
    Elting, J
    Jones, RM
    McHugh, M
    Natrillo, A
    Polony, B
    Vincent, P
    Wilkie, D
    Webb, D
    Zhu, GC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2505 - U2505
  • [36] Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors
    Pinchuk, Boris
    Horbert, Rebecca
    Doebber, Alexander
    Kuhl, Lydia
    Peifer, Christian
    MOLECULES, 2016, 21 (05):
  • [37] Development of thienopyridines as VEGFR-2 kinase inhibitors.
    Munchhof, MJ
    Adams, MA
    Atherton, JA
    Beebe, JS
    Casavant, JC
    Cooper, BC
    Doty, JD
    Emerson, EE
    Foster, BF
    Gant, TG
    Garshasb, SG
    Goodwin, PG
    Harriman, SH
    Higdon, CH
    Hillerman, SH
    Interi, CI
    Jani, JJ
    Knauth, LK
    Marx, MM
    Natarajan, VN
    Noe, MN
    Rossi, AR
    Savage, DS
    Shaeffer, TS
    Smolarek, TS
    Snow, SS
    Sobolov, SS
    Soderstrom, ES
    Sun, JS
    Turncliff, RT
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U197 - U197
  • [38] 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation
    Sobhy, Mahitab K.
    Mowafy, Samar
    Lasheen, Deena S.
    Farag, Nahla A.
    Abouzid, Khaled A. M.
    BIOORGANIC CHEMISTRY, 2019, 89
  • [39] Discovery of novel 5α-reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations
    Wang, Jhih-Lun
    Liu, Hsuan-Liang
    Zhou, Zheng-Li
    Chen, Wei-Hsi
    Ho, Yih
    MOLECULAR SIMULATION, 2015, 41 (04) : 287 - 297
  • [40] Integration of pharmacophore mapping and molecular docking in sequential virtual screening: towards the discovery of novel JAK2 inhibitors
    Yao T.-T.
    Xie J.-F.
    Liu X.-G.
    Cheng J.-L.
    Zhu C.-Y.
    Zhao J.-H.
    Dong X.-W.
    Zhao, J.-H., 1600, Royal Society of Chemistry (07): : 10353 - 10360